{"lastUpdatedAt": 1611081646719, "totalPosts": {"label": "Total Posts", "value": 91}, "totalComments": {"label": "Total Comments", "value": 281}, "postRate": {"title": "Post Rate", "data": [{"label": "2021-01-18T01:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T02:00:00.000+05:30", "value": 6}, {"label": "2021-01-18T03:00:00.000+05:30", "value": 3}, {"label": "2021-01-18T04:00:00.000+05:30", "value": 3}, {"label": "2021-01-18T06:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T07:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T08:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T09:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T10:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T11:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T13:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T14:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T17:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T18:00:00.000+05:30", "value": 2}, {"label": "2021-01-18T19:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T20:00:00.000+05:30", "value": 3}, {"label": "2021-01-18T21:00:00.000+05:30", "value": 1}, {"label": "2021-01-18T22:00:00.000+05:30", "value": 4}, {"label": "2021-01-18T23:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T00:00:00.000+05:30", "value": 6}, {"label": "2021-01-19T01:00:00.000+05:30", "value": 1}, {"label": "2021-01-19T02:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T03:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T04:00:00.000+05:30", "value": 4}, {"label": "2021-01-19T06:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T07:00:00.000+05:30", "value": 3}, {"label": "2021-01-19T08:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T09:00:00.000+05:30", "value": 3}, {"label": "2021-01-19T10:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T12:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T13:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T15:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T17:00:00.000+05:30", "value": 2}, {"label": "2021-01-19T18:00:00.000+05:30", "value": 6}, {"label": "2021-01-19T19:00:00.000+05:30", "value": 5}, {"label": "2021-01-19T20:00:00.000+05:30", "value": 4}, {"label": "2021-01-19T21:00:00.000+05:30", "value": 3}]}, "commentRate": {"title": "Comment Rate", "data": [{"label": "2021-01-19T23:00:00.000+05:30", "value": 216}, {"label": "2021-01-20T00:00:00.000+05:30", "value": 65}]}, "commentSentiments": {"title": "Comment Sentiments", "data": [{"name": "positive", "value": 117}, {"name": "neutral", "value": 111}, {"name": "negative", "value": 53}]}, "postSentiments": {"title": "Post Sentiments", "data": [{"name": "neutral", "value": 53}, {"name": "positive", "value": 31}, {"name": "negative", "value": 7}]}, "topStocks": {"title": "Top stocks", "data": [{"label": "ATOS", "value": 1}, {"label": "ARAY", "value": 1}, {"label": "ACRS", "value": 1}, {"label": "TANH", "value": 2}, {"label": "SINT", "value": 2}, {"label": "BNGO", "value": 2}, {"label": "TRCH", "value": 3}, {"label": "LPCN", "value": 3}, {"label": "ZYXI", "value": 81}]}, "stockRatings": {"title": "Stock Ratings", "data": {"ATOS": {"score": {"P/B": 3, "ROA": 2, "DCF": 5, "P/E": 3, "ROE": 2, "D/E": 5}, "recommendation": {"P/B": "Neutral", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "ARAY": {"score": {"P/B": 3, "ROA": 3, "DCF": 5, "P/E": 3, "ROE": 2, "D/E": 5}, "recommendation": {"P/B": "Neutral", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Neutral"}}, "ACRS": {"score": {"P/B": 5, "ROA": 2, "DCF": 5, "P/E": 3, "ROE": 2, "D/E": 5}, "recommendation": {"P/B": "Strong Buy", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "TANH": {"score": {"P/B": 5, "ROA": 3, "DCF": 5, "P/E": 5, "ROE": 3, "D/E": 5}, "recommendation": {"P/B": "Strong Buy", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Strong Buy", "ROE": "Neutral", "D/E": "Neutral"}}, "SINT": {}, "BNGO": {}, "TRCH": {"score": {"P/B": 5, "ROA": 2, "DCF": 5, "P/E": 3, "ROE": 2, "D/E": 5}, "recommendation": {"P/B": "Strong Buy", "ROA": "Strong Buy", "DCF": "Strong Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "LPCN": {"score": {"P/B": 5, "ROA": 2, "DCF": 4, "P/E": 3, "ROE": 2, "D/E": 4}, "recommendation": {"P/B": "Strong Buy", "ROA": "Buy", "DCF": "Buy", "P/E": "Neutral", "ROE": "Sell", "D/E": "Sell"}}, "ZYXI": {}}}, "enterprise": {"title": "Enterprise History", "data": {"ATOS": {"symbol": "ATOS", "stockPrice": 1.44, "numberOfShares": 8496964.0, "marketCapitalization": 12235628.16, "minusCashAndCashEquivalents": 12581136, "addTotalDebt": 0.0, "enterpriseValue": -345507.83999999985}, "ARAY": {"symbol": "ARAY", "stockPrice": 4.11, "numberOfShares": 87465000, "marketCapitalization": 359481150, "minusCashAndCashEquivalents": 76798000, "addTotalDebt": 159844000, "enterpriseValue": 442527150}, "ACRS": {"symbol": "ACRS", "stockPrice": 1.32, "numberOfShares": 41323921, "marketCapitalization": 54547575.720000006, "minusCashAndCashEquivalents": 35937000, "addTotalDebt": 39078000, "enterpriseValue": 57688575.720000006}, "TANH": {"symbol": "TANH", "stockPrice": 1.43, "numberOfShares": 28853240, "marketCapitalization": 41260133.199999996, "minusCashAndCashEquivalents": 12440460, "addTotalDebt": 7353930, "enterpriseValue": 36173603.199999996}, "SINT": {"symbol": "SINT", "stockPrice": 2.06, "numberOfShares": 1555988.0, "marketCapitalization": 3205335.2800000003, "minusCashAndCashEquivalents": 1787000.0, "addTotalDebt": 12000.0, "enterpriseValue": 1430335.2800000003}, "BNGO": {"symbol": "BNGO", "stockPrice": 1.09, "numberOfShares": 34274469, "marketCapitalization": 37359171.21, "minusCashAndCashEquivalents": 17311373, "addTotalDebt": 0.0, "enterpriseValue": 20047798.21}, "TRCH": {"symbol": "TRCH", "stockPrice": 0.62, "numberOfShares": 72857079, "marketCapitalization": 45171388.98, "minusCashAndCashEquivalents": 89730.0, "addTotalDebt": 11871934, "enterpriseValue": 56953592.98}, "LPCN": {"symbol": "LPCN", "stockPrice": 0.454, "numberOfShares": 25882273, "marketCapitalization": 11750551.942, "minusCashAndCashEquivalents": 9728523.0, "addTotalDebt": 8154448.0, "enterpriseValue": 10176476.942}, "ZYXI": {"symbol": "ZYXI", "stockPrice": 9.73, "numberOfShares": 32439000, "marketCapitalization": 315631470, "minusCashAndCashEquivalents": 14040000, "addTotalDebt": 0.0, "enterpriseValue": 301591470}}}, "profile": {"title": "Company Profile", "data": {"ATOS": {"symbol": "ATOS", "price": 1.39, "beta": 2.45985, "volAvg": 6160395, "mktCap": 99244328, "lastDiv": 0.0, "range": "0.76-5.08", "changes": 0.14, "companyName": "Atossa Therapeutics Inc", "currency": "USD", "cik": "0001488039", "isin": "US04962H5063", "cusip": "04962H506", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://atossatherapeutics.com/", "description": "Atossa Therapeutics, Inc. develops and markets medical devices, laboratory tests, and therapeutics to address breast health conditions in the United States. The company's lead program is the development of Endoxifen, an active metabolite of tamoxifen which is in Phase II studies to treat and prevent breast cancer. It is also developing intraductal microcatheter technology to target the delivery of therapies, including fulvestrant, immunotherapies, and Chimeric Antigen Receptor T-cell therapies, directly to the site of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.", "ceo": "Dr. Steven Quay", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "4", "phone": "12065880256", "address": "107 Spring St", "city": "Seattle", "state": "WASHINGTON", "zip": "98104", "dcfDiff": -3.47, "dcf": 3.36066, "image": "https://financialmodelingprep.com/image-stock/ATOS.png", "ipoDate": "2012-11-08", "defaultImage": false}, "ARAY": {"symbol": "ARAY", "price": 4.77, "beta": 1.9531, "volAvg": 855775, "mktCap": 435375520, "lastDiv": 0.0, "range": "1.33-5.1", "changes": 0.02, "companyName": "Accuray Inc", "currency": "USD", "cik": "0001138723", "isin": "US0043971052", "cusip": "004397105", "exchange": "Nasdaq Global Select", "exchangeShortName": "NASDAQ", "industry": "Medical Devices", "website": "http://www.accuray.com/", "description": "Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.", "ceo": "Mr. Joshua Levine", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "932", "phone": "14087164600", "address": "1310 Chesapeake Ter", "city": "Sunnyvale", "state": "CALIFORNIA", "zip": "94089", "dcfDiff": -4.83, "dcf": 4.39734, "image": "https://financialmodelingprep.com/image-stock/ARAY.jpg", "ipoDate": "2007-02-08", "defaultImage": true}, "ACRS": {"symbol": "ACRS", "price": 17.2707, "beta": 1.45233, "volAvg": 589506, "mktCap": 741246400, "lastDiv": 0.0, "range": "0.7-19.74", "changes": 11.3907, "companyName": "Aclaris Therapeutics Inc", "currency": "USD", "cik": "0001557746", "isin": "US00461U1051", "cusip": "00461U105", "exchange": "Nasdaq Global Select", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://www.aclaristx.com/", "description": "Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.", "ceo": "Dr. Neal Walker", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "75", "phone": "14843247933", "address": "640 Lee Rd Ste 200", "city": "Wayne", "state": "PENNSYLVANIA", "zip": "19087", "dcfDiff": -6.4, "dcf": 5.11964, "image": "https://financialmodelingprep.com/image-stock/ACRS.png", "ipoDate": "2015-10-07", "defaultImage": false}, "TANH": {"symbol": "TANH", "price": 1.92, "beta": 0.35426, "volAvg": 4317580, "mktCap": 68916672, "lastDiv": 0.0, "range": "0.81-3.65", "changes": 0.11, "companyName": "Tantech Holdings Ltd", "currency": "USD", "cik": "0001588084", "isin": "VGG8675X1078", "cusip": "G8675X107", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Coal", "website": "http://www.tantech.cn", "description": "Tantech Holdings Ltd. engages in the development and manufacture of bamboo-based charcoal products. The company is headquartered in Lishui, Zhejiang and currently employs 99 full-time employees. The Company, through its subsidiaries, is a developer and manufacturer of bamboo-based charcoal products for industrial energy applications and household cooking, heating, purification, agricultural and cleaning uses. The firm has three segments: consumer product, trading and biofuel energy. The Consumer products segment manufactures and sells Charcoal Doctor branded products and barbecue (BBQ) charcoal in China. Its products include purification and deodorization products and cleaning products. The Trading segment conducts rubber and other trading businesses. The firm's subsidiary, Tantech Charcoal, is engaged in the trading business. The biofuel energy segment produces and sells BBQ charcoal to customers in Asia, Europe and North America. The company produces and sells bamboo-based fuel for Electric Double-Layer Capacitor (EDLC). Tantech BVI's solid charcoal products are used for purification and deodorization.", "ceo": " Zhengyu Wang", "sector": "Basic Materials", "country": "CN", "fullTimeEmployees": "71", "phone": "865782262309", "address": "No. 10 Cen Shan Rd, Shuige Indtrl Zone, Lishul City", "city": "Lishui", "state": "ZHEJIANG", "zip": null, "dcfDiff": -1.4, "dcf": 2.95335, "image": "https://financialmodelingprep.com/image-stock/TANH.jpg", "ipoDate": "2015-03-24", "defaultImage": true}, "SINT": {"symbol": "SINT", "price": 1.905, "beta": 1.58457, "volAvg": 1676117, "mktCap": 48674844, "lastDiv": 0.0, "range": "0.28-3.3", "changes": 0.145, "companyName": "SINTX Technologies Inc", "currency": "USD", "cik": "0001269026", "isin": "US8293923079", "cusip": "829392307", "exchange": "NasdaqGS", "exchangeShortName": "NASDAQ", "industry": "Medical Devices", "website": "https://www.amedica.com/", "description": "SINTX Technologies, Inc. operates as a commercial biomaterial company. The company is headquartered in Salt Lake City, Utah and currently employs 19 full-time employees. The firm is a vertically integrated silicon nitride orthopedic medical device manufacturer. The company is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. The company is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The firm is incorporating its silicon nitride technology into components for use in total hip and knee replacement product candidates. The firm markets and sells its products to surgeons and hospitals in the United States, and certain markets in Europe and South America. The firm produces silicon nitride for use in its commercial products and product candidates in the various forms, such as solid silicon nitride, porous silicon nitride, composite silicon nitride and silicon nitride coating.", "ceo": "Dr. B. Sonny Bal", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "28", "phone": "18018393516", "address": "1885 West 2100 Street", "city": "Salt Lake City", "state": "UTAH", "zip": "84119", "dcfDiff": null, "dcf": 2.97847, "image": "https://financialmodelingprep.com/image-stock/SINT.jpg", "ipoDate": "2014-02-11", "defaultImage": true}, "BNGO": {"symbol": "BNGO", "price": 9.2605, "beta": 0.0, "volAvg": 63079645, "mktCap": 2106596990, "lastDiv": 0.0, "range": "0.25-9.95", "changes": 0.8305, "companyName": "Bionano Genomics Inc", "currency": "USD", "cik": "0001411690", "isin": "US09075F1075", "cusip": "09075F107", "exchange": "NasdaqCM", "exchangeShortName": "NASDAQ", "industry": "Diagnostics & Research", "website": "https://bionanogenomics.com/", "description": "BioNano Genomics, Inc. is a life sciences instrumentation company, which focuses on genome analysis space. The company is headquartered in San Diego, California and currently employs 77 full-time employees. The firm develops and markets the Saphyr system. The Company\u2019s products include Sequencing for Discovery Research and Cytogenetics. Sequencing alone, however, is significantly limited due to its inability to reveal structural variations. Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response.", "ceo": "DR. R. Erik Holmlin", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "97", "phone": "18588887600", "address": "9540 Towne Centre Dr Ste 100", "city": "San Diego", "state": "CALIFORNIA", "zip": "92121", "dcfDiff": null, "dcf": null, "image": "https://financialmodelingprep.com/image-stock/BNGO.png", "ipoDate": "2018-08-01", "defaultImage": false}, "TRCH": {"symbol": "TRCH", "price": 1.52, "beta": 2.41048, "volAvg": 5581227, "mktCap": 151454624, "lastDiv": 0.0, "range": "0.21-1.58", "changes": 0.15, "companyName": "Torchlight Energy Resources Inc", "currency": "USD", "cik": "0001431959", "isin": "US89102U1034", "cusip": "89102U103", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Oil & Gas E&P", "website": "https://www.torchlightenergy.com/", "description": "Torchlight Energy Resources, Inc. engages in the acquisition, exploration, exploitation and development of oil and natural gas properties in the United States. The company is headquartered in Plano, Texas and currently employs 2 full-time employees. The firm focuses on drilling and working interest programs within the United States. The firm has interests in approximately four oil and gas projects: the Marcelina Creek Field Development in Wilson County, Texas; the Ring Energy Joint Venture in Southwest Kansas; Hunton wells in partnership with Husky Ventures in Central Oklahoma, and the Orogrande Project in Hudspeth County, Texas. The firm also operates through two other subsidiaries, including Torchlight Energy Operating, LLC, a Texas limited liability company, and Hudspeth Oil Corporation, a Texas corporation. The Marcelina Creek Field Development is located over the Austin Chalk, Buda and Eagle Ford Formations.", "ceo": "Mr. John Brda", "sector": "Energy", "country": "US", "fullTimeEmployees": "4", "phone": "12144328002", "address": "5700 W Plano Pkwy Ste 3600", "city": "Plano", "state": "TEXAS", "zip": "75093", "dcfDiff": null, "dcf": 0.0, "image": "https://financialmodelingprep.com/image-stock/TRCH.png", "ipoDate": "2009-10-27", "defaultImage": false}, "LPCN": {"symbol": "LPCN", "price": 1.915, "beta": 0.49783, "volAvg": 2462270, "mktCap": 125789072, "lastDiv": 0.0, "range": "0.301-2.39", "changes": 0.295, "companyName": "Lipocine Inc", "currency": "USD", "cik": "0001535955", "isin": "US53630X1046", "cusip": "53630X104", "exchange": "NASDAQ Capital Market", "exchangeShortName": "NASDAQ", "industry": "Biotechnology", "website": "https://www.lipocine.com/", "description": "Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase 2b testing; LPCN 1148, an oral prodrug of bioidentical testosterone for the treatment of non-alcoholic steatohepatitis cirrhosis (NASH); LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase 2 Clinical trial for the treatment of NASH. Lipocine Inc. is headquartered in Salt Lake City, Utah.", "ceo": "Dr. Mahesh Patel", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "12", "phone": "18019947383", "address": "675 S Arapeen Dr Ste 202", "city": "Salt Lake City", "state": "UTAH", "zip": "84108", "dcfDiff": null, "dcf": 1.70588, "image": "https://financialmodelingprep.com/image-stock/LPCN.jpg", "ipoDate": "2014-03-21", "defaultImage": true}, "ZYXI": {"symbol": "ZYXI", "price": 17.79, "beta": 0.67852, "volAvg": 533546, "mktCap": 618860740, "lastDiv": 0.0, "range": "7.93-29.73", "changes": 1.27, "companyName": "Zynex Inc", "currency": "USD", "cik": "0000846475", "isin": "US98986M1036", "cusip": "98986M103", "exchange": "NasdaqCM", "exchangeShortName": "NASDAQ", "industry": "Medical Devices", "website": "https://www.zynex.com/", "description": "Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also supplies electrodes for the delivery of electrical current to the body and batteries for use in electrotherapy products; and distributes Comfortrac for cervical traction, JetStream for hot/cold therapy, and LSO Back Braces for lumbar support. In addition, it offers blood volume monitor, a non-invasive medical device for monitoring central blood volume for use in operating and recovery rooms to detect blood loss during surgery and internal bleeding during recovery. The company provides its products for use in pain management and control; and stroke and spinal cord injury rehabilitation. Zynex, Inc. sells its products through direct sales force primarily in the United States. The company was founded in 1996 and is headquartered in Englewood, Colorado.", "ceo": "Mr. Thomas Sandgaard", "sector": "Healthcare", "country": "US", "fullTimeEmployees": "283", "phone": "13038673904", "address": "9555 MAROON CIRCLE", "city": "Englewood", "state": "COLORADO", "zip": "80112", "dcfDiff": null, "dcf": 14.1834, "image": "https://financialmodelingprep.com/image-stock/ZYXI.jpg", "ipoDate": "2002-11-27", "defaultImage": true}}}, "news": ["https://www.fool.com/investing/2021/01/19/why-aclaris-therapeutics-stock-skyrocketed-more-th/", "https://www.marketwatch.com/story/aclaris-therapeutics-stock-more-than-triples-after-positive-data-on-arthritis-treatment-trial-2021-01-19", "https://investorplace.com/2021/01/acrs-stock-alert-why-aclaris-therapeutics-is-up-over-200-today/", "https://www.benzinga.com/general/biotech/21/01/19214235/why-aclaris-tenax-gritstone-merus-minerva-and-celyad-are-rallying-today", "https://247wallst.com/healthcare-business/2021/01/19/is-aclaris-therapeutics-a-stock-to-buy-after-nearly-200-run-up-and-now-this/"]}